The IPO Buzz: City Therapeutics (CTY) Upsizes IPO & Prices it at $18 – Mid-Point
City Therapeutics (CTY), a Phase 1 biotech, upsized its IPO at pricing to 11.11 million shares – up from 9.72 million shares in the prospectus – and priced the deal at $18.00 – the mid-point of its range – to raise $199.98 million on Thursday night, Oct. 15, 2026. The RNAi-focused biotech’s stock is expected to start trading tomorrow – Friday, Oct. 16, 2026 – on the NASDAQ. At..
Read more October 15, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| City Therapeutics | CTY | 11.1 | $ 200.0 mil | 10/16/2026 Priced | S/O | S/O |
| TCGX Acquisition Corp. II (Stock-Only) | TCXB | 10.0 | $ 100.0 mil | 10/16/2026 Priced | S/O | S/O |
| Bitari | BIAI | 4.3 | $ 30.0 mil | 10/19/2026 Week of | S/O | S/O |
Last 100 IPOs - October 15, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 39 |
| Number Down: | 59 |
| Number Unchanged: | 2 |
| Percentage Change From Issue Price: | -0.75% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - October 15, 2026
| Number of IPOs priced (Excluding 152 units) : | 130 |
| Number Up: | 48 |
| Number Down: | 80 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | -1.73% |
| The Nasdaq Composite Index YTD % Change | 35.22% |